I-Mab
Yahoo Finance • 7 months ago
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for t... Full story
Yahoo Finance • last year
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discove... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.c... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw... Full story
Yahoo Finance • 2 years ago
10 52-Week Low Stocks to Buy Now
In this article, we discuss 10 52-week low stocks to buy now. If you want to see more stocks in this selection, check out 5 52-Week Low Stocks to Buy Now. The 52-week low for a stock reflects the least closing price the security has trade... Full story
Yahoo Finance • 2 years ago
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announc... Full story
